As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 5/07/04  Stressgen Biotechnologies Corp    8-K:7,12    5/06/04    2:102K                                   Merrill Corp-MD/FA

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     21K 
 2: EX-99       Miscellaneous Exhibit                               HTML     53K 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported):           May 6, 2004

 

STRESSGEN BIOTECHNOLOGIES CORPORATION

(Exact name of registrant as specified in its charter)

 

Yukon Territory, Canada			333-12570		77-0123732
(State or other jurisdiction of incorporation)			(Commission File Number)		(IRS Employer Identification No.)
	350-4243 Glanford Avenue, Victoria, British Columbia					V8Z 4B9
	Parent of Stressgen Biotechnologies, Inc.
	6055 Lusk Boulevard, San Diego, CA					92121
	(Address of principal executive offices)					(Zip Code)
	Registrant’s telephone number, including area code:					(250) 744-2811
						(858) 202-4900

 

 

Item 7. Financial Statements and Exhibits.

 

(c) Exhibits.

 

99.1                           Press release dated May 6, 2004, “Stressgen Biotechnologies Announces First Quarter 2004 Financial Results”

 

Item 12. Results of Operations and Financial Condition.

 

On May 6, 2004 Stressgen Biotechnologies Corporation issued a press release reporting earnings and other financial results for its first fiscal quarter in 2004, which ended March 31, 2004.  A copy of the press release is attached as Exhibit 99.1.

 

This information is furnished pursuant to Item 12 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.  Stressgen has not determined that the reported results are material.

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

	STRESSGEN BIOTECHNOLOGIES CORPORATION
	By:	/s/Gregory M. McKee
Date: May 6, 2004		Vice President, Corporate Development and Chief Financial Officer

 

3

 

INDEX TO EXHIBITS

 

Exhibit No.		Description
99.1		Press release dated May 6, 2004, “Stressgen Biotechnologies Announces First Quarter 2004 Financial Results”

 

4